glp 1 indications Glucagon-Like Peptide-1 Receptor Agonists in Perioperative Care New Molecules and Emerging Indications

World Health Organization issues first-ever guidelines for use of GLP-1 weight loss medications Globally, more than 1 billion people currently live with obesity

Multiple studies suggest these medications are associated with a 15% reduction in weight in just 12 years.3 Many of these drugs are commonly known by their brand name, which has been described in the table below

NAL, a non-selective opioid antagonist [16, 17], is used to reverse opioid overdose effects [18] and precipitates withdrawal in opioid-dependent individuals

Butyrate ameliorated ferroptosis in ulcerative colitis through modulating nrf2/gpx4 signal pathway and improving intestinal barrier